Microbot Medical (MBOT) PT Raised to $12 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Microbot Medical (NASDAQ: MBOT) to $12.00 (from $9.00) while maintaining a Buy rating.

The analyst commented: "Earlier this week, Microbot Medical, one of our top picks for 2H25, announced that the FDA has granted 510(k) clearance for the LIBERTY System, which is the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures. Of note, management plans to start commercialization in the U.S. in 4Q25. The initial addressable market comprises approximately 2.5M peripheral endovascular procedures annually in the U.S. In the pivotal study, LIBERTY showed 100% success in robotic navigation to target and zero device-related adverse events. With LIBERTY, hospitals no longer need dedicated infrastructure and capital equipment to enable access to advanced robotics. Importantly, LIBERTY showed a 92% relative reduction in radiation exposure for physicians in the study. Therefore, LIBERTY has the ability to enhance procedure efficiency, lower costs, and improve overall quality of care for both patients and physicians. Our current estimated market value of the firm is $545M, or approximately $12 per share. Therefore, we reiterate our Buy rating while raising the 12-month price target to $12 from $9 per share."

You May Also Be Interested In

• Q32 Bio Inc. (QTTB) PT Raised to $36 at Mizuho
• Q32 Bio Inc. (QTTB) PT Raised to $40 at Oppenheimer
• Teva lawsuit against Eli Lilly over Forteo revived by appeals court